US00RE38385E

(19) **United States**

(12) **Reissued Patent**

Franks et al.

(10) **Patent Number: US RE38,385 E**

(45) **Date of Reissued Patent: *Jan. 13, 2004**

(54) **STORAGE OF MATERIALS**

(75) Inventors: **Felix Franks**, Cambridge (GB); **Ross H. M. Hatley**, Cambridge (GB)

(73) Assignee: **Nektar Therapeutics**, San Carlos, CA (US)

(*) Notice: This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/939,688**

(22) Filed: **Aug. 28, 2001**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **5,098,893**
Issued: **Mar. 24, 1992**
Appl. No.: **07/479,939**
Filed: **Feb. 12, 1990**

U.S. Applications:

(63) Continuation of application No. 09/270,791, filed on Mar. 17, 1999, now Pat. No. Re. 37,872.

(30) **Foreign Application Priority Data**

Feb. 16, 1989 (GB) 8903593

(51) **Int. Cl.**[7] **A61K 9/26**; A61K 31/715; A61K 38/02; C07K 17/00; C12N 11/00

(52) **U.S. Cl.** **514/54**; 424/94.3; 424/465; 424/486; 424/488; 435/188; 514/21; 514/44; 514/45; 514/48; 514/49; 514/970; 530/427

(58) **Field of Search** 424/440, 459, 424/461, 462, 94.1, 94.3, 400, 486, 487, 488; 514/54, 948, 970, 971, 3, 4, 12, 21, 44, 45, 46, 47, 48, 49, 50, 51, 52; 530/303, 304, 305, 390.5, 397, 399, 427; 435/188

(56) **References Cited**

U.S. PATENT DOCUMENTS

125,714	A	*	4/1872	Allen	424/440
586,504	A	*	7/1897	Marcsch	424/440
1,855,591	A		4/1932	Wallerstein	435/188
2,457,036	A		12/1948	Epstein	426/331
2,648,609	A	*	8/1953	Wurster	424/440
3,300,474	A	*	1/1967	Flodin et al.	536/120
3,413,198	A	*	11/1968	Deutsch	195/103.5
3,456,050	A	*	7/1969	Rieckmann et al.	424/440
3,480,468	A	*	11/1969	Carletti et al.	424/440
3,554,767	A	*	1/1971	Daum et al.	424/440
3,694,547	A	*	9/1972	Forsthoff	924/94.66
4,157,386	A	*	6/1979	La Rochelle	424/49
4,372,942	A	*	2/1983	Cimiluca	424/440
4,423,086	A	*	12/1983	Devos et al.	424/440
4,551,329	A	*	11/1985	Harris et al.	424/440
4,587,267	A	*	5/1986	Drake et al.	514/769
4,741,872	A	*	5/1988	De Luca et al.	424/94.3
4,749,575	A	*	6/1988	Rotman	424/440
4,753,790	A	*	6/1988	Silva et al.	424/440
4,762,719	A	*	8/1988	Forester	424/440
4,824,938	A	*	4/1989	Koyama et al.	530/351
4,847,090	A	*	7/1989	Della Posta et al.	424/440
4,849,225	A	*	7/1989	Mitsuhashi et al.	424/440
4,863,865	A	*	9/1989	Franks	435/240.2
4,873,085	A	*	10/1989	Fuisz	424/440
4,891,319	A	*	1/1990	Roser	435/188
4,898,781	A	*	2/1990	Onouchi et al.	424/94.3
4,910,135	A	*	3/1990	Tischer et al.	435/28
4,963,359	A	*	10/1990	Haslwanter et al.	424/440
4,985,252	A	*	1/1991	Jung et al.	424/440
4,997,654	A	*	3/1991	Corsello et al.	424/440
RE37,872	E	*	10/2002	Franks et al.	514/54

FOREIGN PATENT DOCUMENTS

DE	159826	*	3/1972
EP	0 111 216		6/1984
EP	0140 489		5/1985
EP	0229 810	B1	7/1987
EP	252750	*	1/1988
EP	0 297 887		1/1989
EP	223221	*	3/1989
EP	244771	*	3/1989
EP	0 520 748	A1	12/1992
GB	2 126 588		3/1984
JP	70-12153	B *	1/1970
JP	55-97096		7/1980
WO	8600336	*	1/1986
WO	WO 86/04095		7/1986
WO	8700196	*	1/1987
WO	WO 87/00196		1/1987
WO	WO 87/05300		9/1987
WO	WO 89/06542		7/1989
WO	WO 90/05182		5/1990

OTHER PUBLICATIONS

U.S. patent application Ser. No. 09/270,791, Filed Mar. 17, 1999, Pending.

U.S. patent application Ser. No. 09/939,689, Filed Aug. 28, 2001, Pending.

The Effect of Sugars on the Thermal Dentation of Lysozyme H7H Uedaira Bull chem Soc 53 2451 (1980).

Modes of Stabilization of a Protein by Organic Solutes during Desiccation; John F. Carpenter and John H. Crowe, Department of Zoology, Universtiy of California, Davis, California Crybiology 25 pp. 459–470 (1988).

Principles of "Cryostabilization" Technology from Structure/Property Relationships of Carbohydrate/Water systems—A Review, Harry Levine and Louise Slade, Nabisco Brands, Inc., Corporate Technology Group, Cryoletters 9 pp. 21–63 (1988).

The Glassy State and Survival of Anhydrous Biological Systems, Michael J. Burke, pp. 358–363, (1986) in Membranes, Metabolism, and Dry Organisms, A.C. Leopold, ed.

(List continued on next page.)

Primary Examiner—Jeffrey E. Russel

(74) *Attorney, Agent, or Firm*—Felissa H. Cagan; Richard A. Neifeld; Susan T. Evans

(57) **ABSTRACT**

A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

59 Claims, No Drawings

OTHER PUBLICATIONS

Use of Lyoprotectants in the Freeze–Drying of a Model Protein, Ribonuclease, Michael W. Townsend and Patrick P. DeLuca, Journal of Parenteral Science & Technology, 42 pp. 190–199 (1988).

Structure and Structure Transitions in Dried Carbohydrate Materials, James M. Flink, Physical Properties of Foods, pp. 473–521 (1983).

Some Physico–Chemical Properties of Lactose, B. L. Herrington, J Dairy Science, 17, pp. 501–519, (1934).

The Glassy State in Certain Sugar–Containing Food Products, G.W. White and S.H. Cakebread, J Food Technol. 1 pp. 73–82 (1966).

Loss of Structure in Freeze–dried Carbohydrates Solutions: Effect of Temperature, Moisture Content and Composition, Spyros Tsourouflis, James M. Flink, and Marcus Karel, J Sci Fd–Agric 27, pp. 509–519 (1976).

Structural Stability of Intermediate Moisture Foods—A New Understanding, Louise Slade and H. Levine, Food Structure, its Creation and Evaluation, Blanshard and Mitchell, pp. 115–180 (1988).

The Nature of Glassy State and the Behavior of Liquids at Low Temperatures, Kauzmann Chem Rev 43, pp. 219–227 (1948).

A Polymer Physico–Chemical Approach to the Study of Commercial Starch Hydrolysis Products (SHPs), Harry Levine and Louise Slade, Carbohydrate Polymers, 6 pp. 213–244 (1986).

Stabilization of Phosphofructokinase during Air–Drying with Sugars and Sugar/Transition Metal Mixtures, John f. Carpenter, Beth Martin, Lois M. Crowe, and John H. Crowe, Cryobiology, 24 pp. 455–464 (1987).

Thermostability of Enzyme in the Three–dimensional Network of Polysaccharide Chains, Z. Schneider, A. Stroinski and J. Pawelkiewiz, Bulletin de L'Acad. Polonnaise des Sciences XV1,4 pp. 203 and 204 (1968).

Preservation of the Enzymatic Activity of Rennin during Spray Drying and During Storage, and the Effect of Sugars and Certain Other Additives, M. J. van de Beek and S. Y. Gerlsma, Neth Mild Dairy J. 23 pp. 46–5 (1969).

The Condensed Chemical Dictionary, Seventh Edition, Arthur and Elizabeth Rose, Reinhold Publishing Corporation, p. 448 (1961).

Walter Relations of Foods, R.B. Duckworth, Editor, Academic Press, p. 648 (1975).

The New Encyclopedia Britannica, vol. 16, Encyclopedia Britannica, Inc., pp. 476–479 (1985).

Hydration–induced Conformational and Flexibility Changes of Lysozyme at Low Water Content, P.L. Poole and J.L. Finney, Int J. Biol. Macromol., 5 pp. 308–310 (1983).

Sequential Hydration of a Dry Globular Protein, P.L. Poole and J.L. Finney, Biopolymers, 22 pp. 255–260 (1983).

Protein Hydration and Enzyme Activity: The Role of Hydration–Induced Conformation and Dynamic changes in the Activity of Lysozyme, J.L. Finney and P.L. Poole, Comments Mol Cell Biophys, 2 pages 129–151 (1984).

Dielectric Studies of Protein Hydration and Hydration–induced Flexibility, Bone and Pethig, J. Mol. Biol., 181 pp. 323–326 (1985).

Production of Trehalose Dried Eggs, Quandrant Experimental Data (not dated).

Lyophilization of Biotechnology Products, Arno T. P. Skrabanaja, Andre L. J. De Meere, Rein A. De Ruiter, and Piet J.M. Van Den Detelaar, PDA Journal, 48–6 pp. 311–317 (1994).

Permazyme Technology, Permazyme leaflet (not dated).

BioPharm, Roser, Biopharm, pp. 49–53, Sep. 1991.

Developments in Biological Standardization, Pikal and Sah International Symposium on Biological Products Freeze–Drying and Formulation Bethesda, USA, 74 pp. 165–170 (1991).

Ready–To–To™ DNA Labeling Kit, Promotional Lecture (Not dated).

Analects®, Promotional Lecture (Not dated—1992 or later).

Ready–To–To™ Kits for a broad range of Techniques in Molecular Biology, Designed for results—mot surprises, Promotional Lecture (Not dated).

Psychrometric Chart (not dated).

Green and Angell, J. Phys. Chem, 89, 2880 (1989).

Another View of Trehalose for Drying and Stabilizing Biological Materials, Levine and Slade, BioPharm, 1992.

The Crystalisation of Hydrates From Amorphous Carbohydrates, Barry J. Aldous, Anthony D. Auffret, and Felix Franks, Cryo–Letters, 16 pp. 181–186 (1995).

Physical Characterization of Spray Dried Sugars Suitable A Carriers in Inhalation Systems, Venkatesh Nani, Peter R. Byron and Elaine M. Phillips, Aerosol Research Group, Poster at Tenth annual AAPS, Miami, FL—PT6180 (not dated).

ROOS—Carbohydrate Research, 238, 37–48 (1993).

"The Spray Drying of Enzyme Rennin", Vipin Dhirajlal Shah, University Microfilms, Inc. Ann Arbor Michigan (1963).

Opinion in Inhale v. Quadrant, Case No. HC1999 No. 04555 (Jun. 20, 2001).

Oct. 14, 1999 letter from Mewburn Ellis to EPO.

Sep. 20, 1999 Letter from Gill Jennings & Every to EPO.

Declaration under 37 CFR 1.132 re: Franks et al. Ser. No. 08/241,457; filed May 11, 1994; for storage of materials dated Feb. 23, 1996.

Supplemental Amendment re: Franks et al. Ser. No. 08/241, 457; filed May 11, 1994; for storage of materials dated Apr. 22, 1996.

Document in No. 92 305 769.9—Communication/Minutes (Annex) dated Jul. 17, 1998.

Opposition by Quadrant to Inhale EP 0,383,569; Declaration by Nicholas David Osborne (Unsigned; Sep. 1999).

Opposition by Quadrant to Inhale EP 0,383,569; Declaration by Trevor George Gard (Unsigned; Sep. 1999).

Clas et al. Differential Scanning Calorimentry: Applications in Drug Development,; *Research Focus/Reviews* vol. 2, No. 8, Aug. 1999, pp. 311–320.

Sep. 13, 1999 letter from Gill Jennings & Every to EPO.

Green et al., "The Journal of Physical Chemistry," *Phase Relations and Vitrification in Saccharide—Water Solutions and the Trehalose Anomaly* vol. 93, No. 8, 1989 pp. 2880–2882.

Japanese patent publication Sho 60–244288 (1985–244288) 1985 (translation).

Labrude et al., s.t.p. pharma, Jun. 1988 No. 6; pp. 472–480.

Labrude et al., "Journal of Pharmaceutical Sciences; vol. 78, No. 3, Mar. 1989"; pp. 223–229.

Fax from Eric Potter Clarkson to EPO dated Oct. 15, 1999 re: Further Submissions of Novo Nordisk (Opponent 2).

Oct. 26, 1999 letter/fax from Mewburn Ellis to EPO containing: letter dated Oct. 15, 1999 to EPO form Akzo Nobel.
Nov. 29, 1999 letter from Mewburn Ellis to EPO.
Dec. 3, 1999 letter from Eric Potter Clarkson to EPO re: Opposition to European Patent Application No. 903101561.8 (0383569).
"The Journal of Physical Chemistry," vol. 78, No. 28, 1974; *Dependence of the Glass Transition Temperature on Heating and Cooling Rate*, pp. 2673–2677.
Vo. 41. No. 9, 1968; "Glass Transition in Dehydrated Amorphous Solid", Bull. Chem. Soc. Japan, p. 2322.
Mar. 6, 2000 letter/fax from Mewburn Ellis to EPO.
Nov. 1, 1999 fax from Simmons & Simons, containing claim form and draft amended pleadings.

Hatley et al., Biotechnology & Applied Biochemistry, 11, 367–370 (1989).*

Polinsky et al., Proc. Natl. Acad. Sci. USA, 72, No. 9, 3310–3314 (1975).*

Slade et al., Pure and Applied Chem., 60, No. 12, 1841–1864 (1988).*

Hatley et al., Process Biochemistry, 169–172 (Dec. 1987).*

Pure and Applied Chemistry, vol. 60, 1841–1864, Slade and Levine, "Non–Equilibrium Behaviour of small Carbohydrate Water Systems".*

* cited by examiner

STORAGE OF MATERIALS

Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.

Notice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 5,098,893. The reissue applications are application Ser. No. 09/270,791, and application Ser. Nos. 09/939,688 and 09/939,689, which are continuation reissue applications of application Ser. No. 09/270,791. Application Ser. No. 09/270,791 issued as Re 37,872 on Oct. 8, 2002.

This invention relates to the stabilisation and storage of materials. The principal envisaged field of application is materials employed in the biochemical field and some pharmaceuticals.

A few biologically active materials (e.g. some proteins) are sufficiently stable that they can be isolated, purified and then stored in solution at room temperature. For most materials however this is not possible and some more elaborate form of stabilisation/storage procedure must be used.

A "repertoire" of techniques is known. Not all of them are useful for all materials that give rise to a storage problem. Known storage/stabilisation techniques which are applied to materials after isolation into an aqueous suspension or solution are:

(i) Addition of high concentration of chemical "stabilizer" to the aqueous solution or suspension. Typically 3M ammonium sulphate is used. However, such additives can alter the measured activity of enzymes and can give ambiguous or misleading results if the enzyme is used in a test procedure. (R. H. M. Hatley and F. Franks. Variation in apparent enzyme activity in two-enzyme assay systems: Phosphoenolpyruvate carboxylase and malate dehydrogenase. Biotechnol. Appl. Biochem. 11 367–370 (1989)). In the manufacture of diagnostic kits based on multi-enzyme assays, such additives often need to be removed before the final formulation. Such removal, by dialysis, often reduces the activity of an enzyme.

(ii) Freeze/thaw methods in which the preparation, usually mixed with an additive (referred to as a cryoprotectant) is frozen and stored, usually below −50° C., sometimes in liquid nitrogen. Not all proteins will survive a freeze/thaw cycle.

(iii) Cold storage, with a cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing. For example in the case of restriction endonucleases, the enzymes need to be protected against freezing by the addition of high concentrations of glycerol and maintained at −20° C. Use of an additive in high concentration may also reduce the specificity of restriction enzymes and give rise to so-called "star-activity". (B. Polisky et al. PNAS USA, 72, 3310 (1975)).

(iv) The commonest method for the stabilisation of isolated protein preparations is freeze-drying, but this process can only be applied to freeze-stable products. The aqueous isolate of the active material in a suitable pH buffer and in the presence of a cryoprotectant is first frozen, typically to −40° to −50° C.; the ice is then removed by sublimation under vacuum and at low sub-zero temperatures, following which the residual moisture which may amount up to 50% of the "dried" preparation is removed by desorption during which the temperature gradually rises. The complete freeze-drying cycle may take several days and is costly in capital and energy. Freeze-drying also suffers from technical disadvantages because of its irreproducibility. Suppliers of freeze-dried protein products generally specify storage at −20° C. rather than ambient temperature. Exposure to ambient temperatures for periods of days to weeks can result in significant activity losses.

(v) Undercooling, as described in European Patent 0 136 030 and by Hatley et al. (Process Biochem. 22 169 (1987)) allows for the long-term (years) stabilisation of proteins without the need for additives. However, while this process extended the previous repertoire of possibilities, the undercooled preparations need to be shipped at temperatures not exceeding +5° C. and must be stored, preferably at −20° C. They also have to be recovered from a water-in-oil dispersion prior to their final use.

It will thus be apparent that a stabilisation/storage process which enabled storage at ambient temperature would be very desirable, since it would avoid the need for low temperature storage entailed by existing processes. Hitherto, however, storage at ambient temperature has been impossible for many materials.

There would also be advantage in adding to the existing "repertoire" of processes for stabilisation and storage, because some of the existing processes are limited in their applications or entail accepting disadvantages such as a need to mix with a stabilising agent which is difficult to remove later.

There would furthermore be advantage in providing a more cost effective process than the current freeze-drying process.

We have found, surprisingly, that materials which are not stable when isolated and held in solution at room temperature can nevertheless be successfully incorporated into a glass formed from a water-soluble or water-swellable substance, and can later be recovered. While in the glass the material is immobilised and stable.

In a first aspect this invention provides a storable composition comprising at least one material to be stored, preferably selected from the group consisting of proteins, peptides, nucleosides, nucleotides and enzyme cofactors, dissolved in a water-soluble or water-swellable substance which is in an amorphous, glassy or (much less preferably) rubbery state.

As will be explained in more detail below, it is preferred that the composition displays a glass transition temperature of at least 20° C. preferably at least 30° C.

It may be desirable that the compositions has a water content of not more than 4% by weight.

The invention may be utilised for stable storage of a single material, or for a mixture of materials which have little or no effect on each other.

However, in a development of this invention, a single composition contains a plurality of materials which form part or all of a reacting system. These may be fairly simple chemicals.

In a further aspect, this invention provides a method of rendering a material suitable for storage, comprising dissolving the material in a water-soluble or water-swellable substance or solution thereof and forming the resulting mixture into a glass.

This process is capable of being carried out without the use of any non-aqueous organic solvent, which is advantageous because such solvent could prove harmful to many substances. Also processing with and/or removal of organic solvents can be undesirable for environmental reasons.

A further feature is that the process is energy efficient, requiring much less energy than freeze drying. Most of the drying can be done at less than 40° C.

MATERIAL STORED

The material(s) stabilized for storage may potentially be any of a wide range of materials which are ordinarily liable to undergo a chemical reaction which is dependent on diffusion of reacting species.

One category of materials to which the invention is applicable is proteins and peptides, including derivatives thereof such as glycoproteins. Such proteins and peptides may be any of: enzymes, transport proteins, e.g. haemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides.

Another category of materials to which the invention is applicable comprises nucleosides, nucleotides, dinucleotides, oligonucleotides (say containing up to four nucleotides) and also enzyme cofactors, whether or not these are nucleotides. Enzyme substrates in general are materials to which the invention may be applied.

The material for stabilisation and storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation in artificial culture. Such cells may or may not be genetically transformed cells.

The material will need to be soluble in aqueous solution, at least to the extent of forming a dilute solution which can be used for incorporation into the glass forming substance.

As mentioned above, a development of this invention is to store more than one component of a reacting system in a glass. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.

Storing the materials as a single glassy preparation provides them in a convenient form for eventual use. For instance, if an assay requires a combination of a substrate, or cofactor and an enzyme, two or all three could be stored in a glass in the required concentration ratio and be ready for use in the assay.

If multiple materials are stored, they may be mixed together in an aqueous solution and then incorporated together into a glass. Alternatively they may be incorporated individually into separate glasses which are then mixed together.

When multiple materials are stored as a single composition (which may be two glasses mixed together) one or more of the materials may be a protein, peptide, nucleoside, nucleotide or enzyme cofactor. It is also possible that the materials may be simpler species. For instance a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in aqueous solution they begin to react. If put together in required proportions in the glassy state they do not react and the glass can be stored.

THE GLASS-FORMING SUBSTANCE

A glass is defined as an undercooled liquid with a very high viscosity, that is to say at least 10^{13} Pa.s, probably 10^{14} Pa.s or more.

Normally a glass presents the appearance of a homogeneous, transparent, brittle solid which can be ground or milled to a powder. In a glass, diffusive processes take place at extremely low rates, such as microns per year. Chemical or biochemical changes including more than one reacting moiety are practically inhibited.

Above a temperature known in the glass transition temperature T_g, the viscosity drops rapidly and the glass turns into a rubber, then into a deformable plastic which at even higher temperatures turns into a fluid.

The glass forming substance employed in this invention must be hydrophilic—either water-soluble or water-swellable—so that water will act as a plasticiser. Many hydrophilic materials, both of a monomeric and a polymeric nature either exist as or can be converted into amorphous states which exhibit the glass/rubber transitions characteristic of amorphous macromolecules. They have well defined glass transition temperatures T_g which depend on the molecular weight and a molecular complexity of the glass forming substance. T_g is depressed by the addition of diluents. Water is the universal plasticiser for all such hydrophilic materials. Therefore, the glass/rubber transition temperature is adjustable by the addition of water or an aqueous solution.

For this invention it will generally be necessary that the glass forming substance, when anhydrous or nearly so, displays a glass transition temperature T_g in a range from 20 to 150° C., preferably 25 to 70° C. If T_g is towards the higher end of the range, a lower T_g can be achieved by adding water which can be removed after the material which is to be stored has been incorporated into the glass. Mixtures of glass forming substances may be used if the components are miscible as a solid solution. If so, material(s) of lower T_g serve as plasticiser(s) for material(s) of higher T_g.

If T_g of the final composition is sufficiently high, storage can be at room temperature. However, if T_g of the composition is close to or below room temperature it may be necessary or desirable to refrigerate the glassy composition if storage is for a prolonged period. This is less convenient but still is more economical than freeze-drying.

If the composition is heated above its T_g during storage, it will change to its rubbery state. Even in this condition stored materials are stable for a considerable period of time. Consequently, it may well do no harm if the temperature of the stored material is allowed to go above T_g for a limited time, such as during transportation.

If a composition is maintained above its T_g (and therefore in a rubbery condition) the storage life will be limited but still considerable and the benefit of the invention will be obtained to a reduced extent.

Conversely, if T_g of the composition is well above room temperature, the composition is better able to withstand storage at an elevated temperature, e.g. in a hot climate.

As mentioned above, T_g of the formulated composition is typically 5° below T_g of the anhydrous glass forming substance.

The glass forming substance should be sufficiently chemically inert towards the material which is to be incorporated in it. An absolute absence of chemical reactivity may not be essential, as long as it is possible to incorporate the material, store the glass, and recover the material without serious degradation through chemical reaction.

Many organic substances and mixtures of substances will form a glassy state on cooling from a melt.

Carbohydrates are an important group of glass forming substances: thus candy is a glassy form of sugar (glucose or sucrose). The T_g for glucose, maltose and maltotriose are respectively 31, 43 and 76° C. (L. Slade and H. Levine, Non-equilibrium behaviour of small carbohydrate-water systems, Pure Appl. Chem. 60 1841 (1988)). Water depresses T_g and for these carbohydrates the depression of T_g by small amounts of moisture is approximately 6° C. for each percent of moisture added. We have determined the T_g value for sucrose at 55° C.

In addition to straightforward carbohydrates, other polyhydroxy compounds can be used, such as carbohydrate derivates like sorbitol and chemically modified carbohydrates.

Another important class of glass forming substances are water-soluble or water-swellable synthetic polymers, such as polyvinyl pyrrolidone, polyacrylamide or polyethyleneimine. Here T_g is a function of the molecular weight. Both of these classes of glass forming substances are suitable for the present invention.

A group of glass forming substances which may in particular be employed are sugar copolymers described in U.S. Pat. No. 3,300,474 and sold by Pharmacia under the Registered Trade Mark "Ficoll". This U.S. patent describes the materials as having molecular weight 5,000 to 1,000,000 and containing sucrose residues linked through ether bridges to bifunctional groups. Such groups may be alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms. The bifunctional groups serve to connect sugar residues together. These polymers may for example be made by reaction of the sugar with a halohydrin or a bis-epoxy compound.

One process of rendering a material storage stable in accordance with the present invention commences from an aqueous solution of the material (which will be referred to as the active material), and a supply of the substance into which it is to be incorporated, with this substance already in an amorphous state, either glassy or rubbery.

Then a controlled amount of an aqueous solution containing the active material is incorporated into the glassy substance, thus turning it into a rubber: the materials are mixed to homogenise the glass forming substance with the active material. The rubbery form has the consistency of a dough and can be rolled or milled into a thin sheet. This rubber is then subjected to reduced pressure, possibly accompanied by moderate heat, in order to remove most of the added moisture. The final product is a glass with a glass temperature slightly, e.g. approximately 5°, below that of the pure glass forming substance. It can be kept in the form of a transparent film or ground into a fine powder or compressed into tablet form. In the glassy state (below T_g) the deterioration of the active material, by whatever mechanism, is retarded to the extent that, on practical time-scales, even substances which in their free states are extremely labile are found to possess long shelf-lives.

Full biochemical activity is maintained, but locked in, throughout this period at temperatures below T_g and can be rapidly released by resolubilization of the glass in an aqueous medium.

The glass forming substance and the amount of solution added to it are chosen so that the rubbery material

obtained from the addition is at a temperature above its T_g (or to put it another way, its T_g is below the ambient temperature) but as moisture is removed the value of T_g increases to above the ambient temperature.

Preferably the starting substance also has its T_g above ambient temperature, so that lowering of T_g on addition of aqueous solution lowers this value from above ambient to below. However, it would be conceivable to begin with a moisture-containing substance whose T_g already lies below ambient, lower it further through addition of aqueous solution of the material to be incorporated, and finally raise T_g to above ambient temperature on drying.

The amount of aqueous solution which can and should be added to form a rubbery dough may well be found by trial and error. It is likely to be not more than 5% by weight based on the glass forming substance. The steps of adding solution to form a rubbery dough and drying this back to a glassy state can be repeated to build up the concentration of active material in the glass.

If desired, the T_g value of a sample of a glass forming substance can be determined, and determined again after mixing in varying amounts of water, so as to be able to plot a graph of T_g against moisture content.

T_g values can be determined with a differential scanning calorimeter and can be detected as a point at which a plot of heat input against temperature passes through an inflection point—giving a maximum of the first temperature derivative.

Vacuum applied to assist the removal of water from the rubbery composition need not be particularly hard. Suitably it is less than 90% of normal atmospheric pressure. A pressure which is 80% of normal atmospheric pressure has been found adequate. A harder vacuum may be employed, however, if this is found convenient.

Heating of the doughy mixture to remove moisture may be at a temperature not above 80°, and for a protein is preferably not above 60° C. Heating may not be necessary: evaporation of moisture under reduced pressure may proceed to a sufficiently low moisture content even at room temperature of around 20° C., but of course heat accelerates the evaporation.

Another process for rendering material storage stable in accordance with the present invention can enable the material to be stored and recovered at a greater concentration of active material relative to the carrier substance. In this process a quantity of the carrier substance, or a solution thereof, is added to a solution of the active material. When the added carrier substance has dissolved fully, the solution may be divided into convenient portions, e.g. 0.1 to 1 ml. The samples of solution are placed under reduced pressure so that water is evaporated from them until the carrier substance is in a glassy state. Typical conditions are to commence the evaporation at a temperature not exceeding 40° C., preferably in the range from 20 to 30° C. and continue it for some hours, for instance 24 to 36 hours. As evaporation continues the glass temperature of the residual material rises. Evaporation for the period indicated can be sufficient to achieve a glass transition temperature exceeding 30° C. Once such a sufficiently high glass transition temperature has been achieved the temperature may be raised while evaporation continues. For instance once the glass transition temperature has reached a level of 30° C. the temperature may be raised to within a range of 40 to 70° C., e.g. 60° C. for a shorter time such as two hours. For this procedure also, vacuum used to bring about evaporation of water does not need to be particularly hard. It may also be found that heating is unnecessary: evaporation without heating for an extended time may achieve a sufficiently low moisture content.

In the above, the carrier substance may be added in a dry state, e.g. a powder, or as a solution.

Recovery (i.e. reactivation) of stored material can be effected by simply adding water or aqueous solution to a quantity of the glass with the active material therein. If the carrier substance is water-soluble the result is a solution of the material and the carrier substance.

Separation by chromatography to isolate the stored, active material from the glass forming substance is possible. However, in general it will be neither desirable nor necessary. Instead the glass forming substance is chosen so that it will not interfere with the use (e.g. assay) of the stored, active material.

In the case of a water-swellable glass forming substance, it will remain out of solution, perhaps as a gel, and the solution of the material can be separated by centrifugation if required.

The suitability of an intended glass forming substance and conditions for incorporation of material into it can both be checked by preparing a glass with the material incorporated, and then recovering the material without any substantial period of storage.

Storage stability can, if desired, be tested by storage at a higher temperature such as 35° C. or even 50° C. which gives an accelerated test.

EXAMPLES

In the examples which follow, Examples 1 to 4 illustrate the first process referred to above in which a solution containing the active material is incorporated into the glassy carrier substance, turning it temporarily into a rubbery state. Examples 5 onwards illustrate the second process described above in which the carrier substance is added to a solution of the active material and the resulting solution is then evaporated to the glassy state.

In some of the Examples, material is stored at a temperature above ambient, to provide an accelerated test of storage life.

Examples 1 and 2 describe the storage of lactate dehydrogenase (LDH) which is assayed using a combination of NADH and pyruvate. Example 4 shows the storage of the unstable mixture of NADH with pyruvate. This would provide a suitable material for use in carrying out LDH assays, but in Example 4 that assay procedure is used to confirm the activity of the NADH/pyruvate after storage.

Example 3 describes storage of restriction enzyme, and the activity of the stored enzyme is confirmed by showing that its effect on DNA remains unchanged.

EXAMPLE 1

The glass forming substance employed was Ficoll 400 DL (Pharmacia. Reg. Trade Mark) which is a copolymer of sucrose and epichlorohydrin. It is water-soluble and has a T_g of 97° C. 4 grams of the Ficoll was weighed (w_s) into a dry Universal tube. About 50% was placed into a dry mortar and 0.2 ml of a solution containing 1,000 units/ml lactate dehydrogenase LDH (ex rabbit muscle) in 0.01M phosphate buffer pH 7.0 was added and mixed well into the Ficoll. A further 0.2 ml of LDH solution was then incorporated into the mix. A small amount of Ficoll was added, until a dough was obtained which did not adhere to the pestle. The dough was rolled out on a tile to give a sheet of approx 1 mm thickness. It was separated from the tile with a knife and lightly replaced onto the tile which was then heated in an oven for 30 minutes at 45–50° C. The sheet was removed from the oven and ground to a fine free-flowing powder which was stored in a sealed tube. The unused Ficoll was weighed (w_e). The powder containing the LDH was stored in the laboratory where temperatures fluctuated between 20 and 35° C.

The LDH activity of the powder, assuming no loss of LDH activity, should be given by the relationship:

$$\text{LDH activity (units/grams)} = \text{approx}\frac{0.4\ I}{(w_s - w_c)}$$

where I is the initial concentration of LD in the solution in units/ml.

The actual LDH activity of the powder was assayed. On the assumption that the powder contained negligible moisture, the powder was dissolved in phosphate buffer (0.01M pH 7) to give a test solution calculated to be a 1 to 1,000 dilution of the original solution. This would contain 1 unit of LDH per ml if enzyme activity was entirely preserved. Its actual activity was determined by the following procedure (Hatley, Franks and Mathias, Process Biochemistry, December 1987 page 170).

2.7ml of 0.01M phosphate buffer pH 7, 0.1 ml of 2 mg ml^{-1} NADH, and 0.1 ml of 10 mM pyruvate were placed into a cuvette of path length 10 mm. The cuvette was capped and shaken. 0.1 ml of the test solution was added and the cuvette again capped and shaken. The absorbance at 340 nm was recorded at 30 second intervals for a total period of three minutes. The temperature of the solution was also noted. A period during which the absorbance change was linear with time was selected and the absorbance change per minute, ΔA, calculated. The enzyme activity was calculated as follows:

$$\text{LDH activity (units per milligram)} = \frac{\Delta A \times TCF}{6.25 \times C}$$

where:

ΔA=the absorbance change per minute at 340 nm.

6.25=a correction factor for the molar absorbance of NADH.

TCF=a temperature correction factor which must be applied for assays performed at temperatures other than 25° C.

C=the concentration of the protein (mg ml^{-1}). No loss of LDH activity could be detected after storage for 5 months.

The stability of the product was compared to that of a commercial LDH preparation in 2.1M ammonium sulphate (Type II, 10,000 units/ml ex Sigma) which was stored at 25° C. and assayed periodically by the above method. The activity of this commercial preparation decreased on average by 1.2% per day over the first 45 days.

EXAMPLE 2

A quantity of crystalline sucrose was gently heated to melting on a hotplate under a dry, oxygen-free atmosphere. (Dry nitrogen was used). The sucrose was allowed to cool to give a transparent glass and was then ground into a fine powder, still under a dry atmosphere, and stored in a stoppered tube. 0.4 ml of an LDH solution, containing 4,000 units/ml, in 0.01M phosphate buffer pH 7.0 was added to 4 g of the sucrose glass and mixed using a pestle and mortar. The resulting paste was rolled out on a tile into a thin sheet which was then freed from, and lightly replaced on the tile. It was next heated in an oven for 30 minutes at 40–50° C. after which it was allowed to cool. It was then ground into a fine, free-flowing powder, all operations being performed under the exclusion of moisture. The powder was stored in an air-tight stoppered tube at 25° C. The LDH activity of the powder, assuming no loss of activity, should be given by:

$$\text{LDH activity (units/g solid product)} = \text{approx } 0.1\ I$$

where I is the initial LDH activity (units/ml) in the solution used to prepare the glass.

The preparation was assayed periodically for LDH activity, as described in Example 1. No loss of activity could be detected after 1 month storage at 25° C.

The glass temperature of the preparation was determined by differential scanning calorimetry as 32° C.

EXAMPLE 3

To 1 g Ficoll 400 were added 100 μl of a solution of EcoR I restriction endonuclease in 50% aqueous glycerol and a glass was prepared as described in Example 1. The final preparation was stored for 10 days in the laboratory with temperatures fluctuating between 20 and 30° C.

A quantity of the preparation equivalent to 2 units of enzyme, based on the assumption that the enzyme was still fully active, was dissolved in the following buffer: 100 mM Tris-HCl pH 7.5, 10 mM $MgCl_2$, 50 mM NaCl, 0.1 mg/ml bovine serum albumin. An assay for enzyme activity was carried out by the following procedure (which is taken from LKB Laboratory Manual: LKB 2013 Miniphor Submarine Electrophoresis Unit 1985, Chapter 6). The solution was incubated with 1 μg lamda-DNA for 1 hour at 37° C. Electrophoresis of the incubation mixture was then carried out on Q.5% agarose gel in Tris/borate buffer in standard manner. The DNA breakdown bands observed on the gel corresponded exactly with those of a control run with a fresh enzyme solution.

EXAMPLE 4

A solution containing 100 mg/ml NADH and 33 mg/ml pyruvate was prepared. 0.4 ml of this solution were incorporated into 4 g of a sucrose glass and the mixture processed, as described in Example 2. The mixed glass was stored in 20 mg quantities in spectrophotometer cuvettes which were closed with sealing film and kept in a laboratory where the temperature fluctuated between 20 and 35° C. The glass was stored for 14 days.

For purposes of assay, the contents of a cuvette were dissolved in 2.7ml of 0.01M phosphate buffer (pH 7.0) and 0.1 ml of a LDH solution containing 1 unit/ml was added. The absorbance at 340 nm was recorded at 30 second intervals for a total period of 3 minutes and the temperature of the solution was measured. The apparent LDH enzyme activity was determined from the period during which the absorbance change was linear with time. The activity was calculated as in Example 1. A control assay was carried out with fresh solutions of NADH and pyruvate. The apparent activity obtained using the dissolved glass closely matched the control value.

EXAMPLE 5

The active material was glutamate dehydrogenase. 532 mg of Ficoll 400 DL as used in Example 1 was added to 20 ml of a glutamate dehydrogenase solution, containing 13.3 mg/ml protein. The protein:Ficoll ratio was therefore 1:2. The sample was then divided into eighty 0.25 ml portions and dried at 37° C. under reduced pressure (about 80% of atmospheric) for 24 hours. The sample was then divided into two batches of 40 vials. One batch was heated under reduced pressure for a further two hours at 60° C. The batches were then further subdivided and stored under a range of conditions (see below). Vials were periodically rehydrated by adding 2.23 ml of 50 mM Tris/HCl buffer at pH 7.5, containing 0.3 mM EDTA to give a solution which, assuming no loss of activity, would have contained 100 units of enzyme per ml. This was serially diluted to 1 unit/ml in the same buffer. The actual activity of the recovered enzyme was determined. The assay procedure for recovered enzyme made use of the following solutions:

Solutions

1. 50 mM Tris/HCL pH 7.5+0.3 mM EDTA
2. 4.5 mg/ml NADH in solution 1
3. 4.0125 g NH_4Cl in 25 ml H_2O
4. 97 mg α-ketoglutarate (disodium salt) in 50 ml solution 1.

To carry out the assay 2.6 ml of solution 4, 0.2 ml of solution 3 and 0.1 ml of solution 2 were mixed in a 3 ml cuvette, 0.1 ml of the recovered enzymes solution was added. The absorbance at 340 nm was observed over 5 minutes and the activity of the enzyme calculated from the change (ΔA) in absorbance during the 5 minute period. Activity was calculated using the following formula:

$$\text{Activity (units/ml)} = \frac{\Delta A \times 3}{5 \times 0.622}$$

The results obtained are set out in the following Table in which "initial activity" denotes the activity of enzyme which was recovered after only a minimal period of storage. The activities are quoted as percentages of the theoretical value of activity assuming this had been retained fully. A quantity of a commercially freeze-dried glutamate dehydrogenase (whose activity before freeze drying was stated by the supplier) was divided into several portions and stored at 25° C. for varying periods and assayed in the same way. Its activity is also quoted as percentages of the theoretical activity. The results for this material ar included in the Table.

Process Temperature	Storage Temperature	Initial Activity	Duration of Storage (weeks)					
			1	2	3	4	6	12
37° C.	ambient	97%	95%	99%		98%	86%	
37° C.	35° C.	97%	78%	82%		87%	84%	
37° C.	25° C.	130%	122%	121%	83%	69%		74%
60° C.	ambient	103%	109%	96%		85%	98%	97%
60° C.	35° C.	103%	102%	105%		96%	116%	
60° C.	25° C.	121%	114%	125%	84%	81%		89%
Freeze-dried	25° C.	56%	40%	35%	33%	36%		

As can be seen from these results, experimental error gives rise to some variation in FIGURES, but these do nevertheless show very substantial retention of activity over prolonged storage and much better retention of activity than with freeze-dried material.

EXAMPLE 6

2.50 ml of ascorbate oxidase (21.25 mg protein) solution was prepared. To this was added 2.50 ml of Tris buffer pH 7.6 containing 21.25 mg Ficoll 400, giving a protein:Ficoll weight ratio of 1:1. This was then divided into ten 0.5 ml portions and dried at 37° C. under reduced pressure of about 80% of atmospheric for 24 hours. The samples were next heated, still under reduced pressure, for a further two hours at 60° C. Storage was on a laboratory shelf (temperature fluctuations between 17 and 28° C.). After varying periods of storage, samples were rehydrated by addition of 2.5 ml of 0.4 mM Na_2HPO_4 containing 0.5% Bovine serum albumin. It was then serially diluted in more of the same solution so that its activity would be 0.2 units/ml, if activity had been fully retained, and assayed. The activity relative to the starting value was determined.

Assay was carried out using a standard assay procedure published by Boeringer Mannheim. The assay monitors the decrease in absorbance at 245 nm as the enzyme catalyses the oxidation of a known solution of ascorbic acid. Enzyme

which had been stored for 2 months at 35° C. was found, within the limits of experimental error, to have the same activity as enzyme which was stored for only a very short time.

EXAMPLE 7

Lactate dehydrogenase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 0.23:0.26. Samples were stored for various periods and then recovered by adding 0.01M phosphate buffer in a quantity which would give a theoretical activity of 1 unit/ml, assuming full retention of activity. The recovered solutions were assayed using the procedure set out in Example 1. The measured activity of recovered material, as a percentage of the theoretical activity was:

Before	Storage period (days)					
Drying	1	14	21	28	35	180
100%	91%	81%	91%	112%	97%	98%

EXAMPLE 8

Cytochrome C reductase was incorporated into Ficoll 400 by the procedure of Example 5. The ratio of enzyme:Ficoll was 1:1. Samples were subjected to an accelerated test, viz. stored for 14 days at 35° C., and then recovered by adding 4 ml of 0.2M $KHCO_3$ to give a solution with a theoretical activity of 0.87 unit/ml assuming full retention of activity. The recovered material was assayed using a procedure given in "Methods in Enzymology" by Mahler, Volume II 1955 p. 688. It was found that the recovered material had an activity of 88% of the theoretical value.

EXAMPLE 9

Glycerol-3-phosphate dehydrogenase was incorporated into Ficoll 400 by the procedure of Examples. The ratio of enzyme:Ficoll was 1:2. Samples were subjected to an accelerated storage test by storage at 35° C. After 7 days storage the material was recovered by adding 0.05M Tris/HCl buffer at pH 7.6. This also contained 2 mg/ml albumin and 0.74 mg/ml EDTA. The recovered material was assayed using a procedure published by Biozyme Laboratories in which the enzyme catalyses the reaction:

dihydroxyacetone phosphate–NADH→glycerol-3-phosphate–NAD

and the oxidation of NADH is followed spectrophotometrically at 340 nm.

It was found that after 7 days storage at 35° C. the activity was 96% of the activity of a control sample which was rehydrated immediately after being incorporated into Ficoll.

EXAMPLE 10

Alpha-glucosidase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 1:1. As an accelerated test, samples were stored for various periods at 35° C. and then recovered by adding 4 mls of 0.067M phosphate buffer at pH 7.0 to give a solution whose theoretical activity, assuming full retention of activity, was 2 units/ml. The recovered solutions were assayed by a procedure described by H. Halvorson, Methods in Enzymology 8 559 (1966). The actual activity of recovered material relative to the theoretical value was:

Before	Storage period (days at 35° C.)			
Drying	1	4	11	90
100%	100%	103%	95%	70%

EXAMPLE 11

Pyruvate: 5 g of Ficoll 400 was added to 20 ml of 10 mM sodium pyruvate solution. The solution was then divided into 40 portions, each containing 0.25 ml portions and processed in the manner described for Example 5 to give glasses.

NADH: 5 g of Ficoll 400 was added to 20 ml of a 2 mg/ml NADH solution. This was divided into 40 portions, each containing 0.25 ml, and processed as in Example 5 to give glasses.

At intervals following storage one sample of each reagent was rehydrated and the solutions mixed. They were assayed by the standard method described in Example 4. After 3 months storage at ambient temperature their ability to react in the LDH assay was 100% of the control value obtained at the initiation of storage.

EXAMPLE 12

NADH and pyruvate were processed as in Example 11. Portions of each resulting glass powder were mixed together. One such mixture was at once rehydrated and assayed by the procedure of Example 4. The reaction mixture consisted of 2.8 mls 0.01M phosphate buffer, 0.1 ml of rehydrated NADH/pyruvate mixture, and 0.1 mls of 1 unit/ml enzyme solution. The change in absorbance of 340 nm over three minutes was defined as 100%.

A further mixture was stored for one week and then rehydrated and assayed in the same way. Within the limits of experimental error, its activity was the same. Thus there had been no reaction of the NADH and pyruvate during storage.

EXAMPLE 13

A range of carrier materials were used in a standard procedure in which the stored active material is lactate dehydrogenase. In each case, a solution consisting of 0.05 g of carrier dissolved in 100 ml 0.01M phosphate buffer was prepared. 1 ml of 10 mg/ml lactate dehydrogenase solution was then added to 20 ml of the prepared solution. The solution thus created was divided into 0.5 ml aliquots in glass vials. These were dried under reduced pressure of about 80% atmospheric in a vacuum oven at 36° C. for 24 hours. After drying the vials were sealed and stored at ambient temperature. The product had a carrier:protein ratio by weight of 1:0.22.

Some samples were rehydrated immediately by addition of phosphate buffer. Others were stored for various lengths of time and then rehydrated. The activity of enzyme was determined as in Example 1. Activity of enzyme is expressed, in each case, as activity relative to that of enzyme rehydrated in the first week after drying. Results are set out in the following Table, in which "PVP" denotes polyvinylpyrollidone, "GPS" denotes 6-O-α-D-glucopyranosyl-D-sorbitol. "Palatinit" is a product of Südzucker Aktiengesellschaft. Mannheim-Ochsenfurt, Germany, and consisting of an equimolecular mixture of

α-D-glucopyranosyl-1,6-mannitol and α-D-glucopyranosyl-1,6-sorbitol.

Carrier	Storage period at 25° C. (weeks)									
	1	2	3	4	5	6	8	10	12	16
Maltotrose	100	114		91		96	68	71	101	94
Polydestrose	100	132		123		103	116	146	103	
Inulin	100	99		91		95	114	98	91	
Stachyose	100	122		137		140	109	106	127	
Dextran	100	81		71		89	102	91	95	84
Sorbose	100	93	75	76		55	66	65	58	62
Polyacrylamide	100	100	80		71		53	62	55	63
PVP	100	75		76		70	62			
GPS	100	124								
Palatinit	100	99								

We claim:

[1. A composition which is storage stable at 20° C. comprising:

i) a carrier substance which is water-soluble or water-swellable and is in a glassy amorphous state;

ii) at least one material to be stored, which is unstable in aqueous solution at room temperature of 20° C. dissolved in said amorphous carrier substance, said composition existing in a glassy state at 20° C.**]**

[2. A composition according to claim **1** wherein the material to be stored is selected from proteins, peptides, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors, and derivatives of any of the foregoing having one or more additional moieties bound thereto.**]**

[3. A composition according to claim **1** having a water content not exceeding 4% by weight.**]**

[4. A composition according to claim **1** wherein the composition displays a glass transition temperature of at least 30° C.**]**

[5. A composition according to claim **1** wherein carrier substance is selected from carbohydrates and derivatives thereof which are polyhydroxy compounds.**]**

[6. A composition according to claim **5** wherein the carrier substance is a sugar polymer containing sugar residues linked through ether bridges to bifunctional groups other than carbohydrate.**]**

[7. A composition according to claim **1** wherein the carrier substance is a synthetic polymer.**]**

[8. A composition according to claim **1** wherein said material to be stored comprises a material which is unstable when alone in aqueous solution at room temperature.**]**

[9. A composition according to claim **1** wherein said material to be stored comprises a plurality of materials.**]**

[10. A composition according to claim **9** wherein said material to be stored comprises a plurality of materials which react together in aqueous solution.**]**

[11. A composition according to claim **1** which can be stored without refrigeration for at least 1 week.**]**

[12. A method of rendering a material storage stable at 20° C., which material is unstable in aqueous solution at room temperature of 20° C., comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or in a solution thereof, so that the material is dissolved in said carrier substance, and forming the resulting mixture into a glassy amorphous state, said mixture existing in said glassy state at 20° C.**]**

[13. A method according to claim **12** wherein forming the said mixture into an amorphous state is effected by evaporation under subatmospheric pressure.**]**

[14. A method according to claim **13** wherein evaporation is commenced at a temperature of 20 to 40° C. and subsequently continued at a temperature of 40 to 70° C.**]**

[15. A method according to claim **13** wherein the subatmospheric pressure is not greater than 90% of atmospheric.**]**

[16. In a method of storing a material, which material is unstable in aqueous solution at 20° C., the improvement comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or in a solution thereof, so that the material is dissolved in said carrier substance, forming the resulting mixture into a glassy amorphous state and storing the mixture in said glassy amorphous state without refrigeration for at least one week.**]**

17. A method of rendering a purified biologically active material storage-stable at 20° C., which material is unstable in aqueous solution at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of

(a) a quantity of a purified biologically active material, which material is unstable in aqueous solution at 20° C., which material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto and

(b) a quantity of a carrier substance that is water-soluble or water-swellable;

(2) evaporating liquid water from said aqueous solution, thereby forming a quantity of a composition; and

(3) determining whether said composition formed by said step of evaporating exists in a glassy state at or above 20° C.

18. A method of rendering a purified biologically active material storage-stable at 20° C., which material is unstable in aqueous solution at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of

(a) a quantity of a purified biologically active material, which material is unstable in aqueous solution at 20° C., which material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto, and

(b) a quantity of a carrier substance that is water-soluble or water-swellable;

(2) evaporating liquid water from said aqueous solution, thereby forming a quantity of a composition;

(3) determining whether said composition formed by said step of evaporating has a glass transition temperature at or above 20° C.

19. The method of any of claims 17 and 18 further comprising the steps of:

recovering said purified biologically active material without any substantial storage; and

comparing activity of the recovered purified biologically active material to activity of said purified biologically active material prior to storage.

20. The method of any one of claims 17 and 18 wherein said purified biologically active material is not an enzyme.

21. The method of any one of claims 17 and 18 wherein said purified biologically active material is a peptide or protein other than an enzyme.

22. The method of any one of claims 17 and 18 wherein said purified biologically active material is a hormone other than an enzyme.

23. The method of any one of claims 17 and 18 wherein said purified biologically active material is a blood clotting factor other than an enzyme.

24. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a member selected from the group consisting of immunoglobulin, an enzyme cofactor, a nucleoside, a nucleotide, a dinucleotide, a dimer of a nucleoside, a dimer of a nucleotide, an oligomer of a nucleoside, and an oligomer of a nucleotide.

25. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a hormone.

26. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a transport protein.

27. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a blood clotting factor.

28. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a peptide.

29. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises an enzyme.

30. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a pharmacologically active protein.

31. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a dehydrogenase.

32. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a restriction enzyme.

33. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises an oxidase enzyme.

34. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a reductase enzyme.

35. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a restriction endonuclease.

36. The method of any one of claims 17 and 18 wherein said purified biologically active material comprises a member selected from the group consisting of ascorbate oxidase, cytochrome C reductase, Glycerol-3-phosphate reductase, alpha-glucosidase, and LDH.

37. The method of any one of claims 17 and 18 wherein said carrier substance comprises a member selected from the group consisting of polydextrose, inulin, stachyose, dextran, sorbose, polyacrylamide, GPS, palatinit, and maltotriose.

38. The method of any one of claims 17 and 18 wherein said carrier substance comprises a carbohydrate.

39. The method of any one of claims 17 and 18 wherein said carrier substance comprises a sugar.

40. The method of any one of claims 17 and 18 wherein said carrier substance comprises a polysaccharide.

41. The method of any one of claims 17 and 18 wherein said carrier substance comprises a disaccharide.

42. The method of any one of claims 17 and 18 wherein said step of determining comprises determining whether said composition exists in a glassy state at between 20° C. and 150° C.

43. The method of any one of claims 17 and 18 wherein said step of determining comprises determining whether said composition exists in a glassy state at between 25° C. and 150° C.

44. The method of any one of claims 17 and 18 wherein said step of determining comprises determining whether said composition exists in a glassy state at between 43° C. and 70° C.

45. The method of any one of claims 17 and 18 wherein said step of determining comprises determining whether said composition exists in a glassy state at between 55° C. and 70° C.

46. A method of rendering a purified biologically active material storage-stable at 20° C., which material is unstable in aqueous solution at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of

(a) a purified biologically active material which is unstable in aqueous solution at 20° C. and which is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto and

(b) a carrier substance that is water-soluble or water-swellable;

(2) evaporating liquid water from said solution, thereby converting said solution into a glassy state composition, wherein said glassy state composition exists when at 20° C.;

wherein said evaporating is done without heating; and

wherein said carrier substance comprises a member of the group consisting of inulin, polydextrose, stachyose, dextran, sorbose, polyacrylamide, GPS, and palatinit.

47. A glassy state composition which is storage-stable at 20° C., comprising:

(1) a carrier substance which is water-soluble or water-swellable;

(2) at least one material to be stored which is dissolved in said carrier substance;

wherein said composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C. and is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and

wherein said carrier substance comprises a member of the group consisting of inulin, polydextrose, stachyose, dextran, sorbose, polyacrylamide, GPS, and palatinit.

48. A method of forming a glassy state composition which is storage-stable at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of (a) at least one material to be stored and (b) a carrier substance which is water-soluble or water-swellable;

(2) evaporating water from said solution, thereby forming said glassy state composition;

wherein said glassy state composition including said carrier substance has the property of being in said glassy state and being storage stable when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous

solution at 20° C. and is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleoside or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and

wherein said carrier substance comprises a member of the group consisting of inulin, polydextrose, stachyose, dextran, sorbose, polyacrylamide, GPS, and palatinit.

49. A glassy state composition which is storage-stable at 20° C., comprising:

(1) a carrier substance which is water-soluble or water-swellable;

(2) at least one material to be stored which is dissolved in said carrier substance;

wherein said glassy state composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said glassy state composition contains no more than 4% by weight water; and

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C. and is selected from the group consisting of a hormone, immunoglobulin, a transport protein, a blood clotting factor, an enzyme cofactor, an oxidase enzyme, a reductase enzyme, a dehydrogenase, a restriction enzyme, a nucleoside, a nucleotide, a dinucleotide, a dimer of a nucleoside, an oligonucleotide, and an oligomer of a nucleoside.

50. A method of forming a composition which is storage-stable at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of (a) at least one material to be stored and (b) a carrier substance which is water-soluble or water-swellable;

(2) evaporating water from said solution, thereby forming said glassy state composition;

wherein said glassy state composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said glassy state composition contains no more than 4% by weight water; and

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C. and is selected from the group consisting of a hormone, immunoglobulin, a transport protein, a blood clotting factor, an enzyme cofactor, an oxidase enzyme, a reductase enzyme, a dehydrogenase, a restriction enzyme, a nucleoside, a nucleotide, a dinucleotide, a dimer of a nucleoside, an oligonucleotide, and an oligomer of a nucleoside.

51. A glassy state composition which is storage-stable at 20° C., comprising:

(1) a carrier substance which is water-soluble or water-swellable;

(2) at least one material to be stored which is dissolved in said carrier substance;

wherein said composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C. and is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said at least one material comprises a second biologically active material; and

wherein the first and second biologically active materials react with one another when in aqueous solution with one another.

52. A method of forming a glassy state composition which is storage-stable at 20° C., comprising the steps of:

(1) dissolving to from an aqueous solution of (a) at least one material to be stored and (b) a carrier substance which is water-soluble or water-swellable;

(2) evaporating water from said solution, thereby forming said glassy state composition;

wherein said glassy state composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said at least one material comprises a first purified biologically active material that is unstable in aqueous solution at 20° C. and is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and

wherein said at least one material comprises a second biologically active material, and the first and second biologically active materials react with one another when in aqueous solution with one another.

53. A method of forming a glassy state composition which is storage-stable at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of (a) at least one material to be stored and (b) a carrier substance which is water-soluble or water-swellable;

(2) evaporating water from said solution, thereby forming said glassy state composition;

wherein said glassy state composition including said carrier substance has the property of being in a glassy state and being storage stable when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said at least one material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said glassy state composition contains no more than 4 percent by weight of water; and

shaping said glassy state composition into a shape.

54. The method of claim 53 wherein said shape is a tablet form.

55. The method of claim 54 wherein said at least one material is not an enzyme.

56. A method of rendering a purified biologically active material storage-stable at 20° C. and pharmacologically using said material, which material is unstable in aqueous solution at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of

(a) a purified biologically active material (i) which is unstable in aqueous solution at 20° C. and which is selected from the group consisting of peptides,

proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto and (ii) which is not an enzyme and

(b) a carrier substance that is water-soluble or water-swellable;

(2) forming said solution into a glassy state composition by evaporating liquid water, wherein said glassy state composition exists when at 20° C.; and

(3) administering said purified biologically active material stored in said glassy state composition;

wherein said carrier substance comprises a member selected from the group consisting of inulin, polydextrose, stachyose, dextran, sorbose, polyacrylamide, GPS, and palatinit.

57. A method of rendering a purified biologically active material storage-stable at 20° C. and pharmacologically using said material, which material is unstable in aqueous solution at 20° C., comprising the steps of:

(1) dissolving to form an aqueous solution of

(a) a purified biologically active material (i) which is unstable in aqueous solution at 20° C. and which is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto and (ii) which is not an enzyme and

(b) a carrier substance that is water-soluble or water-swellable;

(2) forming said solution into a glassy state composition by evaporating liquid water, wherein said glassy state composition exists when at 20° C.; and

(3) administering said purified biologically active material stored in said glassy state composition;

wherein said glassy state composition contains no more than 4% by weight water.

58. A process of forming a composition which is storage-stable at 20° C., said composition comprising the steps of:

(1) dissolving to form an aqueous solution

(a) a carrier substance which is water-soluble or water-swellable and

(b) at least one material to be stored;

(2) evaporating liquid water from said solution to convert said solution into a composition in a glassy state;

wherein said composition has the properties that it is storage-stable and exists in said glassy state when at 20° C.;

wherein said composition contains no more than 4 percent by weight of water;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution when at 20° C.;

wherein said at least one material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and

wherein said step of evaporating comprises heating the combined carrier substance and purified biologically active material to a temperature not exceeding 80° C. while maintaining subatmospheric pressure on the combined carrier substance and purified biologically active material.

59. The process of claim 58 wherein said step of evaporating comprises heating the combination to at least 30° C. and not exceeding 80° C.

60. A process of forming a composition which is storage-stable at 20° C., said composition comprising the steps of:

(1) dissolving to form an aqueous solution

(a) a carrier substance which is water-soluble or water-swellable and

(b) at least one material to be stored;

(2) evaporating liquid water from said solution to convert said solution into a composition in a glassy state;

wherein said composition has the properties that it is storage-stable and exists in said glassy state when at 20° C.;

wherein said composition contains no more than 4 percent by weight of water;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution when at 20° C.;

wherein said at least one material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and

wherein said step of evaporating comprises heating the combined carrier substance and purified biologically active material to a temperature not exceeding 80° C.;

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.

61. The process of claim 60 wherein said carrier substance comprises a water soluble or water swellable synthetic polymer.

62. The process of claim 60 wherein said purified biologically active material is not an enzyme.

63. The process of claim 60 wherein said purified biologically active material comprises a hormone.

64. The process of claim 60 wherein said purified biologically active material comprises immunoglobulin.

65. The process of claim 60 wherein said purified biologically active material comprises a blood clotting factor.

66. The process of claim 60 wherein said purified biologically active material comprises a pharmacologically active protein.

67. A glassy state composition which is storage-stable at 20° C., comprising:

(1) a carrier substance which is water-soluble or water-swellable and

(2) at least one material to be stored which is dissolved in said amorphous carrier substance;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said purified biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said composition has the properties that it is storage stable and exists in a glassy state when at 20° C.;

wherein a weight ratio of said purified biologically active material to said carrier substance is between about 2:1 and about 1:1;

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes;

wherein said composition contains no more than four weight percent water.

68. A method of rendering a material storage stable at 20° C. which material is unstable in aqueous solution at room temperature of 20° C., comprising the steps of:

(*1*) *dissolving to form an aqueous solution*

(*a*) *said material and*

(*b*) *a carrier substance which is water-soluble or water-swellable;*

(2) *evaporating liquid water from said solution thereby converting said solution into a glassy state composition;*

wherein said material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said composition has the property that it is storage stable and exists in said glassy state when at 20° C.; and

wherein a weight ratio of said purified biologically active material to said carrier substance is between about 1:2 and about 1:1;

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from restriction enzymes, oxidase enzymes, and reductase enzymes;

wherein said composition contains no more than 4 weight percent water.

69. A composition which is storage-stable at 20° C., comprising:

(*1*) *a carrier substance which is water-soluble or water-swellable;*

(2) *at least one material to be stored which is dissolved in said carrier substance;*

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said composition contains no more than 4 percent by weight of water; and

wherein said biologically active material is not an enzyme.

70. A composition which is storage-stable at 20° C., comprising:

(*1*) *a carrier substance which is water-soluble or water-swellable and*

(2) *at least one material to be stored which is dissolved in said carrier substance;*

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said biologically active material is not an enzyme; and

wherein said carrier substance does not comprise maltotriose.

71. A method of forming a composition which is storage-stable at 20° C., comprising the steps of:

(*1*) *dissolving to form an aqueous solution*

(*a*) *a carrier substance which is water-soluble or water-swellable and*

(*b*) *at last one material to be stored;*

forming said solution into a glassy state composition by evaporating liquid water;

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said biologically active material is not an enzyme; and

wherein said carrier substance does not comprise maltotriose.

72. A composition which is storage-stable at 20° C., comprising:

(*1*) *a carrier substance which is water-soluble or water-swellable and is in a glassy state;*

(2) *at least one material to be stored which is dissolved in said carrier substance;*

wherein said composition exists in a glassy state at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said purified biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said composition contains no more than 4 percent by weight of water; and

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.

73. A composition which is storage-stable at 20° C., comprising:

(*1*) *a carrier substance which is water-soluble or water-swellable and*

(2) *at least one material to be stored which is dissolved in said carrier substance;*

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said composition contains no more than 4 percent by weight of water;

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.

74. A composition which is storage-stable at 20° C., comprising:

(1) *a carrier substance which is water-soluble or water-swellable and*

(2) *at least one material to be stored which is dissolved in said carrier substance;*

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said carrier substance does not comprise maltotriose; and

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.

75. A method of forming a composition which is storage-stable at 20° C., comprising the steps of:

(1) *dissolving to form an aqueous solution*

(a) *a carrier substance which is water-soluble or water-swellable and*

(b) *at least one material to be stored;*

forming said solution into a glassy state composition by evaporating liquid water;

wherein said composition has the property that it exists in a glassy state when at 20° C.;

wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;

wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotide, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;

wherein said carrier substance does not comprise maltotriose; and

with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.

* * * * *